Document is current
Any future updates will be listed below
-
Authors
Hurzeler, Tristan https://orcid.org/0000-0002-6472-6615
Logge, Warren
Watt, Joshua
McGregor, Iain
Suraev, Anastasia
Haber, Paul S.
Morley, Kirsten C.
-
Funding
Funding for this research was provided by:
The University of Sydney
- License Information
-
More Information
Article History
Received: 16 March 2026
Accepted: 11 August 2026
First Online: 1 September 2026
Declarations
Ethical Approval: This study was approved by the Human Ethics Review Committee of the Sydney Local Health District (X19-0416; HREC/16/RPAH/283). All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Declaration of Helsinki and its later amendments.
Consent to Participate: Informed written consent was obtained from all individual participants included in the study following provision of an approved plain language information sheet.
Consent for publication: Not applicable.
Trial registration: This trial was registered at ClinicalTrials.gov (Identifier: NCT05387148; https://clinicaltrials.gov/study/NCT05387148?tab=table).
Competing interests: T.H., W.L., J.W., P.H., and K.M. have no competing interests to disclose. ISM is Academic Director of the Lambert Initiative for Cannabinoid Therapeutics, a philanthropically funded research program at the University of Sydney. He has served as an expert witness in various medicolegal cases involving cannabis and has received consulting fees from Medical Cannabis Industry Australia (MCIA) and Janssen. He currently acts as an advisor/consultant to Kinoxis Therapeutics, Psylo and Emyria. He reports research grants and salary support from the Australian National Health and Medical Research Council (NHMRC) and from Lambert Initiative for Cannabinoid Therapeutics. He is an inventor on patents WO2018107216A1 and WO2017004674A1, licensed to Kinoxis Therapeutics involving use of novel small molecules (non-cannabinoid) to treat addictions and social deficits. ISM also has patents WO2020102857A1 and WO2021042178A1 related to use of small molecules (non-cannabinoid) for treating weight gain and opioid withdrawal, as well as patents WO2019227167 and WO2019071302 issued, which relate to cannabinoid therapeutics. AS has received consulting fees from the Medical Cannabis Industry Australia (MCIA) and Haleon (consumer healthcare subsidiary of Glaxo Smith-Kline).
